Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:ciglitazone
go back to main search page
Accession:CHEBI:64227 term browser browse the term
Definition:An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Synonyms:exact_synonym: 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
 related_synonym: (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione;   Formula=C18H23NO3S;   InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21);   InChIKey=YZFWTZACSRHJQD-UHFFFAOYSA-N;   SMILES=CC1(CCCCC1)COc1ccc(CC2SC(=O)NC2=O)cc1;   ciglitazona;   ciglitazonum
 xref: CAS:74772-77-3;   KEGG:D03493;   LINCS:LSM-1911
 xref_mesh: MESH:C039671
 xref: PMID:20596077;   PMID:21067863;   PMID:21344384;   PMID:21354099;   PMID:21485077;   PMID:21508362;   PMID:21681689;   PMID:21882481;   PMID:22007221;   PMID:22131991;   PMID:22174792;   PMID:22177955;   PMID:22192353;   PMID:22193206;   PMID:22268140;   Reaxys:3623680;   Wikipedia:Ciglitazone



show annotations for term's descendants           Sort by:
ciglitazone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO ciglitazone results in decreased activity of ABCB11 protein CTD PMID:20829430 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA CTD PMID:16197558 NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428
JBrowse link
G Acaa1a acetyl-CoA acyltransferase 1A multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA CTD PMID:16197558 NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
JBrowse link
G Acaa2 acetyl-CoA acyltransferase 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA CTD PMID:16197558 NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
JBrowse link
G Acadm acyl-CoA dehydrogenase medium chain multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA CTD PMID:16197558 NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
JBrowse link
G Acadvl acyl-CoA dehydrogenase, very long chain multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA CTD PMID:16197558 NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA CTD PMID:16197558 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA CTD PMID:16197558 NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] CTD PMID:18162602 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 increases expression ISO ciglitazone results in increased expression of AGPAT2 mRNA CTD PMID:16847310 NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
JBrowse link
G Agt angiotensinogen decreases response to substance EXP ciglitazone results in decreased susceptibility to AGT protein modified form CTD PMID:16820301 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA CTD PMID:16197558 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA CTD PMID:16197558 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 decreases expression EXP ciglitazone results in decreased expression of ALDH1A1 mRNA CTD PMID:22193206 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
JBrowse link
G Ang angiogenin multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA CTD PMID:16197558 NCBI chr15:24,312,711...24,323,361 JBrowse link
G Angptl4 angiopoietin-like 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA CTD PMID:16197558 NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
JBrowse link
G Apom apolipoprotein M multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA CTD PMID:16197558 NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
JBrowse link
G Aqp1 aquaporin 1 decreases expression EXP ciglitazone results in decreased expression of AQP1 mRNA CTD PMID:22193206 NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA CTD PMID:16197558 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA CTD PMID:16197558 NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
JBrowse link
G Atf7ip2 activating transcription factor 7 interacting protein 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA CTD PMID:16197558 NCBI chr10:5,403,099...5,445,989
Ensembl chr10:5,403,105...5,446,142
JBrowse link
G Atp1b1 ATPase Na+/K+ transporting subunit beta 1 decreases expression EXP ciglitazone results in decreased expression of ATP1B1 mRNA CTD PMID:22193206 NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
JBrowse link
G Atp1b3 ATPase Na+/K+ transporting subunit beta 3 decreases expression EXP ciglitazone results in decreased expression of ATP1B3 mRNA CTD PMID:22193206 NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression EXP ciglitazone results in increased expression of BAD protein CTD PMID:12065618 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
affects response to substance
ISO
EXP
[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]
ciglitazone results in increased expression of BAX protein
BAX mRNA affects the susceptibility to ciglitazone
CTD PMID:12065618 PMID:15492468 PMID:21067863 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO ciglitazone results in decreased expression of BCL2 protein CTD PMID:15492468 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl6 BCL6, transcription repressor multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA CTD PMID:16197558 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
JBrowse link
G Bdh1 3-hydroxybutyrate dehydrogenase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA CTD PMID:16197558 NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
JBrowse link
G Bhmt betaine-homocysteine S-methyltransferase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA CTD PMID:16197558 NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein] CTD PMID:21067863 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO ciglitazone results in decreased expression of BIRC5 CTD PMID:17940898 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Blvrb biliverdin reductase B multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA CTD PMID:16197558 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
JBrowse link
G Cadm1 cell adhesion molecule 1 decreases expression EXP ciglitazone results in decreased expression of CADM1 mRNA CTD PMID:22193206 NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
ISO [Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] CTD PMID:15387324 PMID:21067863 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions
increases activity
ISO benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein] CTD PMID:21067863 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein] CTD PMID:21067863 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA CTD PMID:16197558 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA CTD PMID:16197558 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of CCL5 protein] CTD PMID:12624547 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Ccl9 C-C motif chemokine ligand 9 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA CTD PMID:16197558 NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO ciglitazone results in decreased expression of CCNA2 protein CTD PMID:21080969 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnd1 cyclin D1 decreases expression
increases expression
ISO
EXP
ciglitazone results in decreased expression of CCND1
ciglitazone results in decreased expression of CCND1 protein
ciglitazone results in increased expression of CCND1 mRNA
CTD PMID:12787395 PMID:18162602 PMID:20578043 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression
ISO
EXP
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; ciglitazone results in increased expression of and results in increased activity of CDH1 protein
ciglitazone results in decreased expression of CDH1 mRNA
CTD PMID:12391285 PMID:16197558 PMID:22193206 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression
multiple interactions
ISO ciglitazone results in decreased expression of CDK1 protein
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]
CTD PMID:21080969 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression
multiple interactions
ISO
EXP
ciglitazone results in decreased expression of CDK4 protein
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]
ciglitazone results in decreased expression of CDK4 mRNA
CTD PMID:20578043 PMID:21080969 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression
increases expression
ISO ciglitazone results in decreased expression of CDKN1A
ciglitazone results in increased expression of CDKN1A protein
CTD PMID:12787395 PMID:19140230 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression EXP ciglitazone results in increased expression of CDKN1B mRNA CTD PMID:20578043 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression EXP ciglitazone results in increased expression of CEBPB mRNA CTD PMID:22193206 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA CTD PMID:16197558 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Ces1d carboxylesterase 1D decreases expression ISO ciglitazone results in decreased expression of CES1 mRNA CTD PMID:11409902 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
JBrowse link
G Chmp5 charged multivesicular body protein 5 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA CTD PMID:16197558 NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA CTD PMID:16197558 NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA CTD PMID:16197558 NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA CTD PMID:16197558 NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
JBrowse link
G Col10a1 collagen type X alpha 1 chain multiple interactions EXP ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] CTD PMID:16023420 NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
JBrowse link
G Col11a1 collagen type XI alpha 1 chain decreases expression EXP ciglitazone results in decreased expression of COL11A1 mRNA CTD PMID:22193206 NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col4a1 collagen type IV alpha 1 chain decreases expression EXP ciglitazone results in decreased expression of COL4A1 mRNA CTD PMID:22193206 NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
JBrowse link
G Col4a5 collagen type IV alpha 5 chain decreases expression EXP ciglitazone results in decreased expression of COL4A5 mRNA CTD PMID:22193206 NCBI chr  X:105,118,762...105,322,699
Ensembl chr  X:105,118,820...105,322,692
JBrowse link
G Col5a1 collagen type V alpha 1 chain decreases expression EXP ciglitazone results in decreased expression of COL5A1 mRNA CTD PMID:22193206 NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
JBrowse link
G Copa COPI coat complex subunit alpha multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA CTD PMID:16197558 NCBI chr13:84,546,483...84,586,879
Ensembl chr13:84,545,943...84,586,874
JBrowse link
G Cp ceruloplasmin decreases expression EXP ciglitazone results in decreased expression of CP mRNA CTD PMID:22193206 NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
JBrowse link
G Cpm carboxypeptidase M decreases expression EXP ciglitazone results in decreased expression of CPM mRNA CTD PMID:22193206 NCBI chr 7:53,225,647...53,286,220
Ensembl chr 7:53,225,696...53,286,220
JBrowse link
G Crebbp CREB binding protein multiple interactions
affects response to substance
ISO ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]
CREBBP affects the susceptibility to ciglitazone
CTD PMID:21080969 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
JBrowse link
G Cstb cystatin B multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA CTD PMID:16197558 NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526
JBrowse link
G Ctsc cathepsin C multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA CTD PMID:16197558 NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
JBrowse link
G Cyb5r3 cytochrome b5 reductase 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA CTD PMID:16197558 NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA CTD PMID:16197558 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO ciglitazone promotes the reaction [Niflumic Acid results in increased expression of DDIT3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; DDIT3 results in increased susceptibility to [Niflumic Acid co-treated with ciglitazone]; Niflumic Acid promotes the reaction [ciglitazone results in increased expression of DDIT3 protein] CTD PMID:21067863 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dgat1 diacylglycerol O-acyltransferase 1 increases expression ISO ciglitazone results in increased expression of DGAT1 mRNA CTD PMID:16847310 NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions
increases activity
ISO PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein] CTD PMID:19036883 NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA CTD PMID:16197558 NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA CTD PMID:16197558 NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439
JBrowse link
G Dnajb5 DnaJ heat shock protein family (Hsp40) member B5 increases expression EXP ciglitazone results in increased expression of DNAJB5 mRNA CTD PMID:22193206 NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490
JBrowse link
G Dok4 docking protein 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA CTD PMID:16197558 NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression EXP ciglitazone results in increased expression of DUSP1 mRNA CTD PMID:22193206 NCBI chr10:16,680,478...16,683,275 JBrowse link
G Eeig1 estrogen-induced osteoclastogenesis regulator 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EEIG1 mRNA CTD PMID:16197558 NCBI chr 3:15,822,441...15,854,651
Ensembl chr 3:15,823,144...15,854,643
JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 decreases expression EXP ciglitazone results in decreased expression of EFEMP1 mRNA CTD PMID:22193206 NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
JBrowse link
G Efna1 ephrin A1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA CTD PMID:16197558 NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases expression
ISO ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein] CTD PMID:21080969 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation
multiple interactions
ISO ciglitazone results in increased phosphorylation of EIF2A protein
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2A protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2A protein]
CTD PMID:21067863 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation
ISO ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2AK3 protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2AK3 protein] CTD PMID:21067863 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Elf5 E74 like ETS transcription factor 5 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA CTD PMID:16197558 NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973
JBrowse link
G Emp1 epithelial membrane protein 1 increases expression EXP ciglitazone results in increased expression of EMP1 mRNA CTD PMID:22193206 NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
JBrowse link
G Epas1 endothelial PAS domain protein 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA CTD PMID:16197558 NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA CTD PMID:16197558 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fabp4 fatty acid binding protein 4 increases expression ISO ciglitazone results in increased expression of FABP4 mRNA CTD PMID:16847310 NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fads1 fatty acid desaturase 1 multiple interactions
increases expression
ISO [beta-hydroxy simvastatin acid co-treated with ciglitazone] results in increased expression of FADS1 mRNA
ciglitazone results in increased expression of FADS1 mRNA
CTD PMID:17655842 NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
JBrowse link
G Fam13a family with sequence similarity 13, member A multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA CTD PMID:16197558 NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
JBrowse link
G Flnb filamin B multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA CTD PMID:16197558 NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
JBrowse link
G Flnc filamin C increases expression EXP ciglitazone results in increased expression of FLNC mRNA CTD PMID:22193206 NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression
increases expression
ISO
EXP
ciglitazone results in decreased expression of FOS
ciglitazone results in increased expression of FOS mRNA
CTD PMID:12787395 PMID:22193206 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA CTD PMID:16197558 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma increases expression EXP ciglitazone results in increased expression of GADD45G mRNA CTD PMID:22193206 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
JBrowse link
G Galnt2 polypeptide N-acetylgalactosaminyltransferase 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA CTD PMID:16197558 NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
JBrowse link
G Gast gastrin multiple interactions ISO GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] CTD PMID:15387324 NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
JBrowse link
G Gcn1 GCN1 activator of EIF2AK4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA CTD PMID:16197558 NCBI chr12:40,991,512...41,052,661
Ensembl chr12:40,991,512...41,052,555
JBrowse link
G Gk glycerol kinase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA CTD PMID:16197558 NCBI chr  X:50,162,089...50,238,707
Ensembl chr  X:50,163,123...50,238,631
JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA CTD PMID:16197558 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
JBrowse link
G Gramd2b GRAM domain containing 2B multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA CTD PMID:16197558 NCBI chr18:49,884,014...49,981,955
Ensembl chr18:49,884,014...49,981,953
JBrowse link
G Gstm2 glutathione S-transferase mu 2 decreases expression EXP ciglitazone results in decreased expression of GSTM2 mRNA CTD PMID:22193206 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
JBrowse link
G Gys2 glycogen synthase 2 increases expression ISO ciglitazone results in increased expression of GYS2 mRNA; ciglitazone results in increased expression of GYS2 protein CTD PMID:17437057 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA CTD PMID:16197558 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
JBrowse link
G Hamp hepcidin antimicrobial peptide multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA CTD PMID:16197558 NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression EXP ciglitazone results in decreased expression of HIF1A mRNA CTD PMID:22193206 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA CTD PMID:16197558 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA CTD PMID:16197558 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hpn hepsin multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA CTD PMID:16197558 NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
JBrowse link
G Icam1 intercellular adhesion molecule 1 decreases expression ISO ciglitazone results in decreased expression of ICAM1 mRNA; ciglitazone results in decreased expression of ICAM1 protein CTD PMID:17425601 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ier2 immediate early response 2 increases expression EXP ciglitazone results in increased expression of IER2 mRNA CTD PMID:22193206 NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
JBrowse link
G Ifng interferon gamma multiple interactions
decreases secretion
ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein] CTD PMID:12847270 PMID:16844232 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
ISO ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of IL1B protein]
ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]
ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]
CTD PMID:12517972 PMID:12624547 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA CTD PMID:16197558 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Il2 interleukin 2 multiple interactions ISO ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] CTD PMID:21511917 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 multiple interactions ISO ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Mifepristone inhibits the reaction [ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] CTD PMID:15684043 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Il6st interleukin 6 cytokine family signal transducer multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA CTD PMID:16197558 NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] CTD PMID:12847270 NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
JBrowse link
G Itgb5 integrin subunit beta 5 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA CTD PMID:16197558 NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
JBrowse link
G Itih3 inter-alpha trypsin inhibitor, heavy chain 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA CTD PMID:16197558 NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
JBrowse link
G Jag1 jagged canonical Notch ligand 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA CTD PMID:16197558 NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
EXP
ISO
ciglitazone results in increased expression of JUN mRNA
[Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]
ciglitazone results in increased expression of JUN mRNA; ciglitazone results in increased expression of JUN protein
CTD PMID:19698295 PMID:22193206 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Klf4 KLF transcription factor 4 increases expression EXP ciglitazone results in increased expression of KLF4 mRNA CTD PMID:22193206 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Lama1 laminin subunit alpha 1 decreases expression EXP ciglitazone results in decreased expression of LAMA1 mRNA CTD PMID:22193206 NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
JBrowse link
G Lamb2 laminin subunit beta 2 decreases expression EXP ciglitazone results in decreased expression of LAMB2 mRNA CTD PMID:22193206 NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
JBrowse link
G Lgals3 galectin 3 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA CTD PMID:16197558 NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
JBrowse link
G Lif LIF, interleukin 6 family cytokine multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] CTD PMID:19922793 NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA CTD PMID:16197558 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
JBrowse link
G Lmcd1 LIM and cysteine-rich domains 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA CTD PMID:16197558 NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
JBrowse link
G Lox lysyl oxidase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA CTD PMID:16197558 NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
JBrowse link
G Lpcat1 lysophosphatidylcholine acyltransferase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA CTD PMID:16197558 NCBI chr 1:29,766,070...29,816,401
Ensembl chr 1:29,766,071...29,816,401
JBrowse link
G Lpcat3 lysophosphatidylcholine acyltransferase 3 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA CTD PMID:16197558 NCBI chr 4:157,468,397...157,509,889
Ensembl chr 4:157,468,290...157,509,880
JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA CTD PMID:16197558 NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
increases phosphorylation
multiple interactions
ISO
EXP
ciglitazone results in decreased phosphorylation of MAPK1 protein
ciglitazone results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]
CTD PMID:12083801 PMID:19140230 PMID:20578043 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA CTD PMID:16197558 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
decreases expression
multiple interactions
increases phosphorylation
ISO
EXP
ciglitazone results in decreased phosphorylation of MAPK3 protein
ciglitazone results in decreased expression of MAPK3 protein
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]
ciglitazone results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]
CTD PMID:12083801 PMID:19140230 PMID:20578043 PMID:21080969 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA CTD PMID:16197558 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Mogat1 monoacylglycerol O-acyltransferase 1 increases expression ISO ciglitazone results in increased expression of MOGAT1 mRNA CTD PMID:16847310 NCBI chr 9:79,980,963...79,988,513
Ensembl chr 9:79,956,649...79,988,513
JBrowse link
G Mpc1 mitochondrial pyruvate carrier 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA CTD PMID:16197558 NCBI chr 1:52,437,745...52,449,399
Ensembl chr 1:52,437,741...52,449,400
JBrowse link
G Mpzl2 myelin protein zero-like 2 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA CTD PMID:16197558 NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298
JBrowse link
G Mtmr4 myotubularin related protein 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA CTD PMID:16197558 NCBI chr10:72,393,411...72,416,342
Ensembl chr10:72,392,551...72,416,342
JBrowse link
G Mxra8 matrix remodeling associated 8 decreases expression EXP ciglitazone results in decreased expression of MXRA8 mRNA CTD PMID:22193206 NCBI chr 5:166,448,919...166,453,645
Ensembl chr 5:166,449,154...166,453,636
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
ISO CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] CTD PMID:21080969 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions
affects response to substance
ISO ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]
NCOA1 affects the susceptibility to ciglitazone
CTD PMID:21080969 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
JBrowse link
G Ndrg2 NDRG family member 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA CTD PMID:16197558 NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
decreases activity
ISO ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein]
ciglitazone results in decreased activity of NFKB1 protein
CTD PMID:17425601 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha decreases expression ISO ciglitazone results in decreased expression of NFKBIA protein CTD PMID:12517972 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] CTD PMID:12031542 PMID:12847270 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Npc1 NPC intracellular cholesterol transporter 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA CTD PMID:16197558 NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA CTD PMID:16197558 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein] CTD PMID:12839938 NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 affects localization ISO ciglitazone affects the localization of NR3C1 protein CTD PMID:15684043 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Nrep neuronal regeneration related protein multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA CTD PMID:16197558 NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA CTD PMID:16197558 NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517
JBrowse link
G Optn optineurin multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA CTD PMID:16197558 NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
JBrowse link
G Osmr oncostatin M receptor multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA CTD PMID:16197558 NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262
JBrowse link
G Pakap paralemmin A kinase anchor protein multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA CTD PMID:16197558 NCBI chr 5:72,536,986...72,648,524
NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]; ciglitazone results in increased cleavage of and results in increased activity of PARP1 protein; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein] CTD PMID:15492468 PMID:21067863 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA CTD PMID:16197558 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Pdzk1 PDZ domain containing 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA CTD PMID:16197558 NCBI chr 2:184,376,161...184,407,514
Ensembl chr 2:184,376,161...184,407,514
JBrowse link
G Phka2 phosphorylase kinase regulatory subunit alpha 2 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA CTD PMID:16197558 NCBI chr  X:34,170,959...34,293,498
Ensembl chr  X:34,171,323...34,293,466
JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA CTD PMID:16197558 NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA CTD PMID:16197558 NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
JBrowse link
G Pla2g2a phospholipase A2 group IIA multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA CTD PMID:16197558 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
JBrowse link
G Plac8 placenta associated 8 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA CTD PMID:16197558 NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264
JBrowse link
G Plcxd1 phosphatidylinositol-specific phospholipase C, X domain containing 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA CTD PMID:16197558 NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392
JBrowse link
G Plin2 perilipin 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA CTD PMID:16197558 NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 decreases expression EXP ciglitazone results in decreased expression of PLOD2 mRNA CTD PMID:22193206 NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
JBrowse link
G Plscr4 phospholipid scramblase 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA CTD PMID:16197558 NCBI chr 8:92,987,290...93,026,056
Ensembl chr 8:92,987,381...93,026,049
JBrowse link
G Pmm1 phosphomannomutase 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA CTD PMID:16197558 NCBI chr 7:113,466,632...113,477,004
Ensembl chr 7:113,466,632...113,477,022
JBrowse link
G Pnrc1 proline-rich nuclear receptor coactivator 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA CTD PMID:16197558 NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161
JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA CTD PMID:16197558 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
increases expression
decreases expression
ISO ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]
ciglitazone results in decreased expression of PPARA mRNA
CTD PMID:11056218 PMID:11840453 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
increases activity
increases localization
affects binding
decreases response to substance
affects localization
ISO
EXP
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EEIG1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HCAR3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; ciglitazone binds to and results in decreased activity of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; monobutyl phthalate inhibits the reaction [ciglitazone binds to and results in increased activity of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; norathyriol inhibits the reaction [ciglitazone results in increased activity of PPARG protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein]; Quercetin inhibits the reaction [ciglitazone results in increased activity of PPARG protein]
ciglitazone results in increased expression of PPARG mRNA; ciglitazone results in increased expression of PPARG protein
[ciglitazone binds to and results in increased activity of PPARG protein] which results in increased transport of Glucose; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Glycerol results in decreased expression of PPARG protein]
[ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA]
ciglitazone results in increased localization of PPARG protein
PPARG protein mutant form results in decreased susceptibility to ciglitazone
ciglitazone affects the localization of PPARG protein
CTD PMID:11030710 PMID:11343236 PMID:11683414 PMID:11840453 PMID:12391285 More... NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions
ISO ciglitazone results in increased expression of PPARGC1A mRNA
PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA]
CTD PMID:16513826 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA CTD PMID:16197558 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
JBrowse link
G Prodh proline dehydrogenase increases expression ISO ciglitazone results in increased expression of PRODH mRNA CTD PMID:17535976 NCBI chr11:82,910,043...82,927,305
Ensembl chr11:82,910,137...82,927,305
JBrowse link
G Psd4 pleckstrin and Sec7 domain containing 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA CTD PMID:16197558 NCBI chr 3:7,137,069...7,173,571
Ensembl chr 3:7,137,155...7,173,571
JBrowse link
G Pten phosphatase and tensin homolog increases expression EXP ciglitazone results in increased expression of PTEN protein CTD PMID:20578043 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
JBrowse link
G Ptger3 prostaglandin E receptor 3 multiple interactions ISO [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGER3 CTD PMID:21681689 NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
JBrowse link
G Ptges prostaglandin E synthase multiple interactions ISO [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGES CTD PMID:21681689 NCBI chr 3:14,177,892...14,189,236 JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
affects expression
increases expression
ISO
EXP
2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGS2; ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; ciglitazone results in increased expression of and results in increased activity of PTGS2 protein; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of and results in increased activity of PTGS2 protein]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein]
ciglitazone affects the expression of PTGS2 protein
ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; ciglitazone promotes the reaction [PAR-1-activating peptide results in increased expression of PTGS2 protein]
ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; ciglitazone results in increased expression of PTGS2 mRNA; ciglitazone results in increased expression of PTGS2 protein
CTD PMID:11840453 PMID:12031542 PMID:12517972 PMID:16417216 PMID:19954759 More... NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pxdn peroxidasin decreases expression EXP ciglitazone results in decreased expression of PXDN mRNA CTD PMID:22193206 NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase increases activity ISO ciglitazone results in increased activity of RAF1 protein CTD PMID:12083801 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Rarb retinoic acid receptor, beta multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]; NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] CTD PMID:12839938 NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
JBrowse link
G Rbms1 RNA binding motif, single stranded interacting protein 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA CTD PMID:16197558 NCBI chr 3:45,195,828...45,420,406
Ensembl chr 3:45,197,972...45,420,376
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases activity
multiple interactions
ISO ciglitazone results in decreased activity of RELA protein
ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein]
CTD PMID:17425601 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Retsat retinol saturase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA CTD PMID:16197558 NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
JBrowse link
G Rnase4 ribonuclease A family member 4 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA CTD PMID:16197558 NCBI chr15:24,312,765...24,330,112
Ensembl chr15:24,312,464...24,330,117
JBrowse link
G Rnf10 ring finger protein 10 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA CTD PMID:16197558 NCBI chr12:41,341,708...41,375,505
Ensembl chr12:41,341,717...41,375,504
JBrowse link
G Rnf128 ring finger protein 128 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA CTD PMID:16197558 NCBI chr  X:103,183,643...103,298,431
Ensembl chr  X:103,183,831...103,298,423
JBrowse link
G Rps6kc1 ribosomal protein S6 kinase C1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA CTD PMID:16197558 NCBI chr13:102,346,160...102,491,000
Ensembl chr13:102,346,160...102,490,303
JBrowse link
G Sec23a Sec23 homolog A, COPII coat complex component multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA CTD PMID:16197558 NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
JBrowse link
G Sema3g semaphorin 3G multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA CTD PMID:16197558 NCBI chr16:6,413,589...6,425,221
Ensembl chr16:6,413,589...6,425,221
JBrowse link
G Septin10 septin 10 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA CTD PMID:16197558 NCBI chr20:27,101,764...27,194,997
Ensembl chr20:27,101,752...27,194,780
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA CTD PMID:16197558 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
JBrowse link
G Slc24a2 solute carrier family 24 member 2 decreases expression EXP ciglitazone results in decreased expression of SLC24A2 mRNA CTD PMID:22193206 NCBI chr 5:101,497,916...101,741,840
Ensembl chr 5:101,502,278...101,739,337
JBrowse link
G Slc24a4 solute carrier family 24 member 4 decreases expression EXP ciglitazone results in decreased expression of SLC24A4 mRNA CTD PMID:22193206 NCBI chr 6:121,279,590...121,419,811
Ensembl chr 6:121,280,031...121,414,949
JBrowse link
G Slc30a10 solute carrier family 30, member 10 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA CTD PMID:16197558 NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103
JBrowse link
G Slc4a7 solute carrier family 4 member 7 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA CTD PMID:16197558 NCBI chr15:10,585,307...10,664,780
Ensembl chr15:10,588,979...10,664,781
JBrowse link
G Slc50a1 solute carrier family 50 member 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA CTD PMID:16197558 NCBI chr 2:174,677,985...174,680,366
Ensembl chr 2:174,677,708...174,680,366
JBrowse link
G Snrk SNF related kinase multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA CTD PMID:16197558 NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323
JBrowse link
G Sod3 superoxide dismutase 3 decreases expression EXP ciglitazone results in decreased expression of SOD3 mRNA CTD PMID:22193206 NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
JBrowse link
G Sorl1 sortilin related receptor 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA CTD PMID:16197558 NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
JBrowse link
G Sowahc sosondowah ankyrin repeat domain family member C multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA CTD PMID:16197558 NCBI chr20:27,195,198...27,199,664
Ensembl chr20:27,193,743...27,265,018
Ensembl chr20:27,193,743...27,265,018
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA CTD PMID:16197558 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srxn1 sulfiredoxin 1 increases expression EXP ciglitazone results in increased expression of SRXN1 mRNA CTD PMID:22193206 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
ISO [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein] CTD PMID:19698295 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] CTD PMID:19922793 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Stbd1 starch binding domain 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA CTD PMID:16197558 NCBI chr14:15,470,452...15,473,857
Ensembl chr14:15,469,582...15,477,443
JBrowse link
G Stx7 syntaxin 7 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA CTD PMID:16197558 NCBI chr 1:21,197,075...21,237,320
Ensembl chr 1:21,197,075...21,237,279
JBrowse link
G Sun2 Sad1 and UNC84 domain containing 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA CTD PMID:16197558 NCBI chr 7:111,275,374...111,292,565
Ensembl chr 7:111,275,380...111,292,553
JBrowse link
G Tbc1d4 TBC1 domain family, member 4 multiple interactions
increases phosphorylation
ISO
EXP
[ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA
ciglitazone results in increased phosphorylation of TBC1D4 protein
CTD PMID:16197558 PMID:18063688 NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
JBrowse link
G Tcaf1 TRPM8 channel-associated factor 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA CTD PMID:16197558 NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:18162602 PMID:27936102 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tgif1 TGFB-induced factor homeobox 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA CTD PMID:16197558 NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802
JBrowse link
G Thra thyroid hormone receptor alpha decreases activity EXP ciglitazone results in decreased activity of THRA protein CTD PMID:16023420 NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA CTD PMID:16197558 NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
JBrowse link
G Tmbim1 transmembrane BAX inhibitor motif containing 1 multiple interactions ISO [ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA CTD PMID:16197558 NCBI chr 9:75,871,835...75,889,366
Ensembl chr 9:75,871,835...75,889,069
JBrowse link
G Tmem53 transmembrane protein 53 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA CTD PMID:16197558 NCBI chr 5:130,721,780...130,737,692
Ensembl chr 5:130,721,659...130,737,692
JBrowse link
G Tnfrsf12a TNF receptor superfamily member 12A increases expression EXP ciglitazone results in increased expression of TNFRSF12A mRNA CTD PMID:22193206 NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
JBrowse link
G Tns1 tensin 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA CTD PMID:16197558 NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225
JBrowse link
G Tpm3 tropomyosin 3 increases expression EXP ciglitazone results in increased expression of TPM3 mRNA CTD PMID:22193206 NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
JBrowse link
G Traf3ip2 Traf3 interacting protein 2 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA CTD PMID:16197558 NCBI chr20:43,011,405...43,054,654
Ensembl chr20:43,011,450...43,054,667
JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression EXP ciglitazone results in increased expression of TRIB3 mRNA CTD PMID:22193206 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Ucp2 uncoupling protein 2 decreases expression ISO ciglitazone results in decreased expression of UCP2 mRNA CTD PMID:11056218 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Ucp3 uncoupling protein 3 decreases expression ISO ciglitazone results in decreased expression of UCP3 mRNA CTD PMID:11056218 NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA CTD PMID:16197558 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA CTD PMID:16197558 NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
increases expression
ISO [[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; [Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA
ciglitazone results in increased expression of VEGFA mRNA
CTD PMID:16197558 PMID:18599600 PMID:21681689 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vnn1 vanin 1 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA CTD PMID:16197558 NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO ciglitazone results in decreased expression of XIAP CTD PMID:17940898 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
G Zfp185 zinc finger protein 185 multiple interactions ISO [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA CTD PMID:16197558 NCBI chr  X:150,831,869...150,877,652
Ensembl chr  X:150,831,862...150,874,810
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19918
    role 19894
      application 19729
        pharmaceutical 19565
          drug 19565
            antineoplastic agent 17770
              ciglitazone 232
Path 2
Term Annotations click to browse term
  CHEBI ontology 19918
    subatomic particle 19916
      composite particle 19916
        hadron 19916
          baryon 19916
            nucleon 19916
              atomic nucleus 19916
                atom 19916
                  main group element atom 19866
                    p-block element atom 19866
                      carbon group element atom 19811
                        carbon atom 19806
                          organic molecular entity 19806
                            organic molecule 19758
                              organic cyclic compound 19565
                                organic heterocyclic compound 18906
                                  organic heteromonocyclic compound 17826
                                    thiazolidines 8137
                                      thiazolidinone 7815
                                        ciglitazone 232
paths to the root